Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group

Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients. Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 1999-10, Vol.86 (8), p.1463
Hauptverfasser:	Feliu, J, López Gómez, L, Madroñal, C, Espinosa, E, Espinosa, J, Girón, C G, Martínez, B, Castro, J, De la Gándara, I, Barón, M G
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cisplatin Contraindications Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Neoplasm Staging Neutropenia - chemically induced Peripheral Nervous System Diseases - chemically induced Thrombocytopenia - chemically induced Treatment Outcome Vinblastine - adverse effects Vinblastine - analogs & derivatives Vinblastine - therapeutic use Vinorelbine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!